The Charcot Foot as a Complication of Diabetic Neuropathy

Current Diabetes Reports

Volumn 14, Issue 12, 2014, Pages 1-9

  Mascarenhas, Janice V ^a,b   Jude, Edward B ^a,b  

^a TAMESIDE AND GLOSSOP INTEGRATED CARE NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Charcot neuroarthropathy; Diabetic peripheral neuropathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

AUTONOMIC NEUROPATHY; BONE; CHARCOT FOOT; CONSERVATIVE TREATMENT; DELAYED DIAGNOSIS; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIAGNOSTIC ERROR; EVOLUTION; HUMAN; HYPERGLYCEMIA; IMMOBILIZATION; INJURY; JOINT DESTRUCTION; METABOLISM; MOTOR NEUROPATHY; NEUROPATHIC JOINT DISEASE; OSSIFICATION; OSTEOLYSIS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETIC FOOT; MULTIMODAL IMAGING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETIC FOOT; DIABETIC NEUROPATHIES; HUMANS; MULTIMODAL IMAGING;

EID: 84920882319     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0561-6     Document Type: Review

References (52)

1. Ziegler D, Rathmann W, Dickhaus T, et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31:464–9.
2. Giacco F, Brownlee M. Pathogenesis of microvascular complications. Textbook of diabetes. 4th edition. Hoboken (NJ): Wiley-Blackwell; 2010.
3. Armstrong DG, Todd WF, Lavery LA, et al. The natural history of acute Charcot’s arthropathy in a diabetic foot specialty clinic. Diabet Med. 1997;14:357–63.
4. Sanders LJ, Frykberg RG. Charcot neuroarthropathy of the foot. Levin and O’Neal’s the diabetic foot. 6th edition. St Louis (MO): Mosby; 2001; p. 439–65.
5. Trepman E, Nihal A, Pinzur MS. Current topics review: Charcot neuroarthropathy of the foot and ankle. Foot Ankle Int. 2005;26:46–63.
6. Pinzur MS. Current concepts review: Charcot arthropathy of the foot and ankle. Foot Ankle Int. 2007;28:952–9.
7. Chantelau E, Onvlee GJ. Charcot foot in diabetes: farewell to the neurotrophic theory. Horm Metab Res. 2006;38:361–7.
8. Eckel RH, Wassef M, Chait A, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group II: pathogenesis of atherosclerosis in diabetes. Circulation. 2002;105:e138–43.
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.
10. Kumar P, Rao GN, Pal BB, et al. Hyperglycemia-induced oxidative stress induces apoptosis by inhibiting PI3-kinase/Akt and ERK1/2 MAPK mediated signaling pathway causing downregulation of 8-oxoG-DNA glycosylase levels in glial cells. Int J Biochem Cell Biol. 2014;53C:302–19.
11. Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment. A report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Phys Ther. 2008;88(11):1436–43.
12. Ziegler D. Diabetic peripheral neuropathy. Textbook of diabetes. 4th edition. Hoboken (NJ): Wiley-Blackwell; 2010.
13. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14:953–61.
14. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci U S A. 1981;78:5190–2.
15. Edmonds ME, Morrison N, Laws JW, et al. Medial arterial calcification and diabetic neuropathy. Br Med J (Clin Res Ed). 1982;284:928–30.
16. Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int. 2012;23(2):635–41. This study illustrates that patients with type 2 DM have poor bone quality despite a higher BMD.
17. Wimalawansa SJ. Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. Ann NY Acad Sci. 2007;1117:283–97.
18. Grant WP, Sullivan R, Sonenshine DE, et al. Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. J Foot Ankle Surg. 1997;36:272–8. Discussion: 330.
19. Joseph AL, Ernesto C, Lawrence GR. Metabolic bone disease. Williams textbook of endocrinology. 12th edition. Philadelphia: Elsevier; 2011; p. 1310.
20. Petrova NL, Shanahan CM. Neuropathy and the vascular-bone axis in diabetes: lessons from Charcot osteoarthropathy. Osteoporos Int. 2014;25:1197–207.
21. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22:157–62.
22. Thomas CC, Eichenholtz SN. Charcot joints. Springfield (IL):1966.
23. Johnson JE. Operative treatment of neuropathic arthropathy of the foot and ankle. J Bone Joint Surg Am. 1998;80:1700–9.
24. Schon LC, Easley ME, Weinfeld SB. Charcot neuroarthropathy of the foot and ankle. Clin Orthop Relat Res. 1998;349:116–31.
25. Schlossbauer T, Mioc T, Sommerey S, Kessler SB, Reiser MF, Pfeifer KJ. Magnetic resonance imaging in early stage Charcot arthropathy—correlation of imaging findings and clinical symptoms. Eur J Med Res. 2008;13:409–14.
26. Foltz KD, Fallat LM, Schwartz S. Usefulness of a brief assessment battery for early detection of Charcot foot deformity in patients with diabetes. J Foot Ankle Surg. 2004;43(2):87–92.
27. Rogers LC, Bevilacqua NJ. Imaging of the Charcot foot. Clin Podiatr Med Surg. 2008;25:263–74.
28. Bramham R, Wraight P, May K. Management of Charcot neuroarthropathy. Diabet Foot J. 2011;14(4):163–70. This is a review article which emphasizes on timely intervention in the management of both acute and chronic CF.
29. Sanders LJ, Mrdjenovich D. Anatomical patterns of bone and joint destruction in neuropathic diabetics. Diabetes. 1991;40:529A.
30. Sanders LJ, Frykberg RG. Diabetic neuropathic osteoarthropathy: Charcot foot. In: Levin ME, O’Neal LW, Bowker JH, editors. The high risk foot in diabetes mellitus. New York: Churchill Livingstone; 1991. p. 297–338.
31. Rogers LC, Frykberg RG, Armstrong DG, et al. The Charcot foot in diabetes. Diabetes Care. 2011;34:2123–9. This article is a recent consensus statement by the ADA which provides treating clinicians with an overview of the pathophysiology of CF. It also highlights the use of appropriate diagnostic techniques and therapeutic interventions to be applied according to various stages of CF.
32. Kimmerle R, Chantelau E. Weight-bearing intensity produces Charcot deformity in injured neuropathic feet in diabetes. Exp Clin Endocrinol Diabetes. 2007;115:360–4.
33. Armstrong DG, Lavery LA. Monitoring healing of acute Charcot’s arthropathy with infrared dermal thermometry. J Rehabil Res Dev. 1997;34:317–21.
34. Giurini JM. Applications and use of in-shoe orthoses in the conservative management of Charcot foot deformity. Clin Podiatr Med Surg. 1994;11:271–8.
35. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45:1–66.
36. Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care. 2001;24:1019–22.
37. Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733–59.
38. Lehenkari PP, Kellinsalmi M, Napankangas JP, et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002;61:1255–62.
39. Itzstein C, Coxon FP, Rogers MJ. The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases. 2011;2:117–30.
40. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80–100.
41. Selby PL, Young MJ, Boulton AJ. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med. 1994;11:28–31.
42. Jude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia. 2001;44:2032–7.
43. Pitocco D, Ruotolo V, Caputo S, et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care. 2005;28:1214–5.
44. Zaidi M, Inzerillo AM, Moonga BS, et al. Forty years of calcitonin—where are we now? A tribute to the work of Iain Macintyre, FRS. Bone. 2002;30:655–63.
45. Kapurniato A, Taylor JW. Structural and conformational requirements for human calcitonin activity. Design, synthesis and study of lactam bridge analogs. J Med Chem. 1995;38:836–47.
46. Bem R, Jirkovska A, Fejfarova V, et al. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care. 2006;29:1392–4.
47. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153–61.
48. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–11.
49. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.
50. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602.
51. Dinarello CA. Blocking interleukin-1b in acute and chronic autoinflammatory diseases. J Intern Med. 2011;269:16–28.
52. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63:1062–8.